Case Study on the Role of Probiotic Supplementation in Managing Irritable Bowel Syndrome (IBS)

Abstract

Irritable Bowel Syndrome is the most prevalent functional gastrointestinal disorder, symptoms of which are diagnosed with abdominal pain, bloating, diarrhea, and constipation. It has increasingly emerged as evidence that gastrointestinal microbiota imbalances contribute to the pathophysiology of IBS. Other therapies applied to overcoming the same symptoms include probiotic supplementation through the restoration of gut microbial balance. The case report is concerned with the role of probiotics in the management of IBS in a 35-year-old woman who showed marked improvement in symptoms after supplementation of probiotics for 12 weeks. This case report tries to correlate the probable benefits of probiotics and gives deep insights into creating or tailoring an individualized approach for the treatment of an IBS patient.

Introduction

IBS causes annoyance and lowers the quality of life for millions of people around the world; its pathophysiology is multifactorial. The main factors are gut microbiota imbalance, visceral hypersensitivity, and altered gut-brain interactions. Live microorganisms that confer health benefits when administered in adequate amounts are termed probiotics. It has a case discussion to identify the effectiveness of probiotic supplementation in the management of IBS symptoms. Then, an overview of how modulation of gut microbiota may be beneficial for improving patient outcomes is provided.

Patient Information

This patient is a 35-year-old female patient who complained of recurrent gastrointestinal symptoms in the past 3 years in the form of bloating, abdominal pain, and episodes of diarrhea and constipation alternatively occurring. She has no significant family history of gastrointestinal diseases; however, she finds some improvement with stress and certain food triggers such as dairy and fatty foods. Her BMI is within the limits and does not have any other known medical conditions.

Clinical Findings

She was subjected to various investigations: blood, stool, and colonoscopy that altogether excluded inflammatory bowel disease as well as other organic GI diseases. Her symptoms resulted in the diagnosis of IBS, especially mixed type, where there is an alternating course between diarrhea and constipation.

Timeline

Week 0: Initial consultation and diagnosis of IBS-M.

Week 1: Initiation of a daily probiotic supplement containing Lactobacillus acidophilus and Bifidobacterium bifidum.

Week 4: Follow-up visit; mild improvement in bloating and abdominal pain, but constipation persists.

Week 8: Marked reduction in abdominal pain and bloating; fewer episodes of diarrhea.

Week 12: Significant overall symptom improvement; fewer episodes of constipation and diarrhea, with improved bowel regularity.

Diagnostic Assessment

The Rome IV criteria were used for diagnosis focusing specifically on recurrent abdominal pain with concomitant or preceding alteration of bowel habits that occurs at least for three months. A background clinical history and exclusion through other examinations such as colonoscopy, blood tests, and stool analysis supported the diagnosis of IBS-M.

Follow-Up and Outcomes

After 12 weeks of probiotic supplementation, she was relieved of IBS symptoms altogether. The episodes of bloating and abdominal pain decreased in frequency and intensity, and she experienced fewer fluctuations between diarrhea and constipation. She was recommended to continue probiotic supplementation and dietarily modify to avoid known triggers like dairy and fatty foods. She is followed up regularly to monitor her progress and treat in the light of changes.

Discussion

This case suggests that probiotic supplementation may be beneficial for the improvement of IBS symptoms. Probiotics can modulate the gut microbiota by encouraging the growth of good bacteria and reducing inflammation, improving the motility of the gut, and enhancing barrier function in the gut. In this patient, Lactobacillus acidophilus and Bifidobacterium bifidum were used in combination. Studies have indicated that these strains have been useful in patients to alleviate symptoms of IBS, primarily bloating and abdominal pain.

Probiotics have been confirmed by many randomized controlled trials as a valid treatment for IBS, though the efficacy of probiotics can vary depending on the strain dosage, and duration of treatment. In this case, with significant improvement in her symptoms after 12 weeks, it is possible to consider probiotics as an option that could alleviate symptoms in IBS patients. However, heterogeneity and variability in IBS make it imperative that treatment plans be personalized because different patients might have a response to different probiotic strains or even interventions.

Takeaway

Indeed, probiotic supplementation could be an effective tool for the management of IBS symptoms, but probably mainly as an adjunctive treatment in mild to moderate disease. The improvement in this patient's condition suggests that modulation of gut microbiota may help alleviate some of the suffering associated with IBS. However, more research is needed to better understand specific strains and mechanisms on which they exert the benefit. Such individualized treatment plans, aimed at the patient's specific microbiota profile and pattern of symptoms and triggers, could assist patients with IBS to live better lives.

Patient’s Perspective

The patient remains satisfied with the outcome of her treatment, and she feels an improvement in her quality of life. She said that the diminution of bloating and pain improved her ability to participate in daily activities and that bowel regularity reduced anxiety about the unpredictability of gastrointestinal symptoms. She said that she found it relatively easy to integrate the probiotic supplement into her lifestyle and would be quite receptive to continuing this approach in the long-term management of IBS.

Conclusion

The patient in the current case demonstrates the feasibility of probiotics supplementation in treating IBS symptoms in patients who have an imbalance of gut microbiota. The substantial improvements demonstrated by this patient in abdominal pain, bloating, and bowel regularity in 12 weeks highlight the significant therapeutic potential of probiotics. Further work is needed to identify which are the more effective strains and treatment protocols, but the case supports probiotics as a form of treatment that could be utilized in personalized treatment plans for IBS patients.

References

Ford, A. C., Harris, L. A., Lacy, B. E., & Quigley, E. M. (2018). Systematic review with meta-analysis: The efficacy of prebiotics, probiotics, synbiotics, and antibiotics in irritable bowel syndrome. Alimentary Pharmacology & Therapeutics, 48(10), 1044-1060. doi:10.1111/apt.15001.

Pinto-Sanchez, M. I., & Bercik, P. (2011). Probiotics and prebiotics in irritable bowel syndrome (IBS): Where are we? Journal of Clinical Gastroenterology, 45(Supplement 3), S139-S143. doi:10.1097/MCG.0b013e3182274136.

Simrén, M., Barbara, G., Flint, H. J., Spiegel, B. M., Spiller, R. C., Vanner, S., ... & Zoetendal, E. G. (2013). Intestinal microbiota in functional bowel disorders: A Rome foundation report. Gut, 62(1), 159-176. doi:10.1136/gutjnl-2012-302167.

Didari, T., Mozaffari, S., Nikfar, S., & Abdollahi, M. (2015). Effectiveness of probiotics in irritable bowel syndrome: Updated systematic review with meta-analysis. World Journal of Gastroenterology, 21(10), 3072-3084. doi:10.3748/wjg.v21.i10.3072.

Hod, K., Ringel, Y., & van Tilburg, M. A. (2016). Probiotics in functional bowel disorders. Current Gastroenterology Reports, 18(8), 40. doi:10.1007/s11894-016-0513-y.

Guo, Q., Goldenberg, J. Z., Humphrey, C., El Dib, R., & Johnston, B. C. (2020). Probiotics for the prevention of antibiotic-associated diarrhea in children. Cochrane Database of Systematic Reviews, 11(11), CD004827. doi:10.1002/14651858.CD004827.pub5.

Mazzawi, T., & El-Salhy, M. (2017). Effect of multi-strain probiotics on the symptoms and the quality of life in patients with irritable bowel syndrome: A randomized double-blind placebo-controlled trial. European Journal of Gastroenterology & Hepatology, 29(3), 356-362. doi:10.1097/MEG.0000000000000812.

Khanna, R., & Rafferty, L. (2018). Probiotic therapy in irritable bowel syndrome: A systematic review and meta-analysis of randomized, controlled trials. American Journal of Gastroenterology, 113(3), 421-430. doi:10.1038/ajg.2018.23.

Hungin, A. P. S., Mulligan, C., Pot, B., Whorwell, P., Agréus, L., Fracasso, P., ... & de Wit, N. (2013). Probiotics in the management of lower gastrointestinal symptoms in clinical practice: A systematic review and consensus. Alimentary Pharmacology & Therapeutics, 38(8), 864-886. doi:10.1111/apt.12460.

McFarland, L. V., & Dublin, S. (2008). Meta-analysis of probiotics for the treatment of irritable bowel syndrome. World Journal of Gastroenterology, 14(17), 2650-2661. doi:10.3748/wjg.14.2650.

Read more such content on @ Hidoc Dr | Medical Learning App for Doctors